Underdiagnosis and undertreatment of osteoporotic patients admitted in internal medicine wards in Italy between 2010 and 2016 (the REPOSI Register)

Jessica Pepe [1] · Pasquale Agosti[2] · Cristiana Cipriani[1] · Mauro Tettamanti[3] · Alessandro Nobili[3] ·
Luciano Colangelo[1] · Rachele Santori[1] · Mirella Cilli[1] · Salvatore Minisola[1] · Reposi investigators

Abstract

Purpose To evaluate clinical features, treatments, and outcomes of osteoporotic patients admitted to internal medicine and geriatric wards compared with non-osteoporotic patients (REPOSI registry).

Methods We studied 4714 patients hospitalized between 2010 and 2016. We reported age, sex, educational level, living status, comorbidities and drugs taken, Cumulative Illness Rating Scale (CIRS), Barthel Index, Short-Blessed Test, 4-item Geriatric Depression Scale, serum hemoglobin, creatinine, and clinical outcomes. Osteoporosis was defined based on the diagnoses recorded at admission, according to the following ICD9: 733, 805–813, 820–823.

Results Twelve percent of the patients had a preadmission diagnosis of osteoporosis. Only 20% of these had been prescribed oral bisphosphonates; 34% were taking vitamin D supplements. Osteoporotic patients were significantly older, with lower BMI, higher CIRS, and taking more drugs. They were significantly more depressed, less independent, with a higher severity of cognitive impairment compared with non-osteoporotic patients. At discharge, the number of patients receiving treatment for osteoporosis did not change. Length of stay and inhospital mortality did not differ between groups. Osteoporotic patients were more frequently nonhome discharged compared with those without osteoporosis (14.8 vs. 7.9%, $p = 0.0007$), mostly discharged to physical therapy or rehabilitation (8.8 vs. 2.5% of patients, $p < 0.0001$). Among osteoporotic patients deceased 3 months after discharge, the number of those treated with vitamin D, with or without calcium supplements, was significantly lower compared with survivors (12 vs. 32%, $p = 0.0168$).

Conclusions The diagnosis of osteoporosis is poorly considered both during hospital stay and at discharge; osteoporotic patients are frailer compared to non-osteoporotic patients.

Keywords Osteoporosis · Fractures · Bisphosphonates · Vitamin D

Introduction

In Europe, the prevalence of osteoporosis is estimated to be between 5.9 and 7.2% in men and between 19.1 and 23.5% in women, respectively; this percentage significantly increases in older people [1]. However, osteoporosis is often not diagnosed until a fragility fracture occurs, and many patients remain untreated, even after osteoporotic fractures arise [2]. Less than

✉ Jessica Pepe
jessica.pepe@uniroma1.it

1 Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, "Sapienza" University of Rome, Rome, Italy

2 Department of Pathophysiology and Transplantation, Fondazione

IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, and Fondazione Luigi Villa, Università degli Studi di Milano, Milan, Italy

3 Neuroscience Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy

one-third of postmenopausal women and fewer men are prescribed bone-active drugs to reduce fracture risk [3, 4]. In particular, the oldest old may be undertreated for osteoporosis, as shown by a nationwide population study based on a registry of drug prescriptions which comprised all of the Sweden population [5]. The probability of use of bisphosphonates declined with increasing age, and indeed for osteoporotic patients age ≥90 years versus those of 75–79 years, the OR for prescription of bisphosphonates was 0.36 (95% CI 0.34–0.38) for women and OR 0.46 (95% CI 0.37–0.56) for men. However, studies have shown that it is cost-effective to treat osteoporosis at higher ages [6]. This is an important issue facing demographic changes in western countries where elderly people represent a large part of the entire population.

It should be noted that more than 95% of the adults with osteoporosis have at least one coexisting disease [7]. In a cohort of 1467 subjects, considering several diseases, such as osteoporosis, hypertension, and type 2 diabetes mellitus, with a mean follow-up time of 4 years, according to the multivariate analysis, osteoporosis was the most important risk factor for all-cause mortality, followed by diabetes and hypertension [8].

Some studies have indicated that the excess mortality, after hip fracture, may be linked to complications following the fracture and to pre-fracture comorbid conditions [9]. However, other studies attempting to adjust for these factors have found an unexplained excess mortality [10].

There is evidence that drugs usually prescribed for osteoporosis, such as bisphosphonates, reduce not only hip fracture incidence but also mortality [11], as shown in different settings including outpatient clinics [12, 13] and intensive care units [14]. However, a recent meta-analysis failed to demonstrate such an effect of bisphosphonates on mortality [15].

Data showing characteristics of osteoporotic patients have been conducted only in out-patients or in long-term care facilities. Previous studies have shown that in long-term facilities osteoporotic patients reported a fracture rate 8–9 fold higher than those observed among less impaired seniors [16], the vast majority being undertreated [17, 18]. However, there are no data on sociodemographic and clinical features and outcomes of osteoporotic patients hospitalized in internal medicine wards.

Therefore, this study was carried out to evaluate clinical features, treatments, and outcomes of osteoporotic patients, regardless of the reason for admission to internal medicine and geriatric wards, compared with non-osteoporotic patients.

Methods

Data collection

The REPOSI register (Registro Politerapie SIMI) is a collaborative and independent initiative of the Italian Society of Internal Medicine (SIMI), the IRCCS Istituto di Ricerche Farmacologiche Mario Negri and the IRCCS Ca' Granda Maggiore Policlinico Hospital Foundation. The registry was set up in 2008 with the voluntary participation of doctors working in internal medicine and geriatric wards; all patients investigated and included in the registry were required to sign an informed consent.

Physicians contributing to the REPOSI Register fill out a standardized web-based case report form which includes: sociodemographic variables, treatments at hospital admission, in hospital and at discharge, laboratory parameters, comorbidities, clinical events occurring during hospital stay, and outcomes [19]. Comorbidity burden was defined according to the Cumulative Illness Rating Scale (CIRS), Comorbidity Index (CI), and Severity Index (SI) [20, 21]. Polypharmacy was defined as five or more medications [19].

To better characterize the population studied, we utilized the same clinical score previously utilized in the other REPOSI papers [19]. The Barthel Index (BI) was used for measuring functional dependence in the basic activities of daily living, partitioning dependence into five levels: total (scores 0–24), severe (scores 25–49), moderate (scores 50–74), mild (scores 75–90), and minimal (scores 91–100) [22]. As a measure of cognitive impairment, the short-blessed test (SBT) was used, with the following standard cut-off points: normal cognition (score 0–4), possible cognitive deficit (score 5–9), probable cognitive deficit (score ≥ 10) [23]. For mood evaluation, we utilized the 4-item Geriatric Depression Scale (GDS-4), rating patient mood as probable absence of depression (0), minor (1), and probable depression (≥2) [24]. Biochemical evaluation included serum hemoglobin and creatinine; creatinine clearance (CrCl) was estimated by using the CKD-EPI equation. Osteoporosis was ascertained, using the diagnoses recorded at admission as reported by the patients, according to the following ICD9 codes corresponding to the diagnosis of osteoporosis and atraumatic fractures: 733, 805–813, 820–823. Those that reported fracture of skull, fingers and toes were not considered osteoporotic [25].

Patients were followed up for 3 months after discharge by a telephone interview in order to collect information.

Statistical analysis

Categorical variables were described using numbers and percentages. Continuous variables were expressed as mean values ± standard deviations (SDs). At uni-variable level the differences in proportions and medians were evaluated with chi-square or Fisher (where appropriate) and Mann–Whitney tests, respectively. The relation between osteoporosis and the outcomes was also adjusted for age, sex and CIRS CI by logistic regression or linear regression (where appropriate) in multivariable models. Statistical

analyses were carried out using JMP Pro 14 (SAS Institute Inc. Cary. NC. USA). P values < 0.05 were considered statistically significant. Missing data were reported in the tables.

Results

Demographic and clinical characteristics of patients

We included all the patients (4714) enrolled in the REPOSI Registry between 2010 and 2016 in Italy. For 561 out of the 4714 (12%) patients, a diagnosis of osteoporosis was recorded as a comorbidity at admission (Table 1A). Patients with osteoporosis were significantly older, mainly females and with a lower BMI compared with non-osteoporotic patients. A higher proportion of osteoporotic patients lived alone, had a caregiver and reported a previous hospitalization (Table 1A). Osteoporotic patients showed a statistically significant mean higher CIRS SI and CIRS CI; however, only mean CIRS SI values persisted significantly higher when osteoarticular diseases were excluded. Moreover, they were taking more drugs with respect to those without a diagnosis of osteoporosis (Table 1A).

Concerning the biochemical profile, osteoporotic patients had statistically significant mean lower serum hemoglobin and creatinine levels; however, creatinine may be related to different BMI, indeed, no significant difference in the proportion of patients in each K-DOQI classes was found compared to non-osteoporotic patients (Table 1B).

Patients with osteoporosis were significantly more depressed; furthermore, we found that there was a statistically significant higher proportion of patients with cognitive impairment and that osteoporotic patients were significantly more dependent compared with non-osteoporotic patients (Table 1B).

Drug therapies for osteoporosis

Before admission, 20% of osteoporotic patients took bisphosphonates, only two patients (0.4%) denosumab and two patients (0.4%) teriparatide. Vitamin D supplementation was prescribed in 34% of osteoporotic patients, of whom 14.5% in combination with calcium supplements; only 6% of patients took calcium supplementation alone (Table 2). Interestingly, the number of patients treated for osteoporosis, during hospitalization and at discharge, remained largely unchanged (Table 2).

In-hospital and 3 months clinical outcomes

Length of stay in medicine wards was not different for osteoporotic compared to non-osteoporotic patients (Table 3); however, the discharge of osteoporotic patients to nursing homes or rehabilitation units was significantly more prevalent ($p < 0.0001$). Among the 3 months outcomes, a higher functional decline was observed in osteoporotic patients, with a trend near to significance (Table 3).

Considering osteoporotic patients, we found a statistically significant higher rate of inhospital mortality in the following subgroups: males ($p = 0.007$), those who lived with a caregiver ($p = 0.02$), previous hospitalization ($p = 0.03$) or admitted from institution ($p = 0.04$), severely dependent ($p = 0.008$) and in those with kidney failure (0.004) (Supplementary Table 1).

Osteoporotic patients who died after 3 months follow-up, compared to osteoporotic patients who survived, were significantly older (84.5 ± 7.9 vs. 79.8 ± 7.8 $p = 0.0017$), with a higher proportion of patients with a BMI lower than $25\,kg/m^2$ (70.4 vs. 50.2%, $p = 0.0445$), and with lower mean serum hemoglobin levels (10.9 ± 1.8 vs. 11.7 ± 2.1, $p = 0.0187$). Furthermore, a higher proportion of osteoporotic patients, admitted from nursing homes, died after 3 months (11.4 vs. 3.7%, $p = 0.0565$).

Osteoporosis drugs and in-hospital and 3 months clinical outcomes

Inhospital mortality, among osteoporotic patients treated with bisphosphonates, did not differ from that of patients without treatment (2.7 vs. 4.1% $p = 0.63$). Among osteoporotic patients, those who had undergone preadmission treatment with bisphosphonates had a statistically significant lower comorbidity burden, a better renal function, were less dependent, and had a lower rate of previous hospitalization (Table 4). Among osteoporotic patients deceased 3 months after discharge, the number of those treated with vitamin D, with or without calcium supplements, was significantly lower compared with survivors (12 vs. 32%, $p = 0.0168$).

Discussion

In our study, we found that 12% of patients admitted to internal medicine wards had a concomitant diagnosis of osteoporosis, of whom only 20% had undergone a preadmission treatment with bone-active agents.

The key message from our findings is that, in Italy, osteoporosis is underdiagnosed and undertreated in patients admitted and discharged from internal medicine wards. Indeed, based on osteoporosis prevalence in Europe and more specifically in Italy (ranging from 25 to 50% in the elderly), we would have expected a higher percentage of diagnosis of this common metabolic bone disease in the elderly [26, 27]. However, it can be correctly stated that,

Table 1 **A** Main features of patients with osteoporosis compared with those without. **B** Biochemical and functional parameters of patients with osteoporosis compared with those without

A	$N = 561$ Osteoporosis	$N = 4153$ No osteoporosis	p	Missing values
Age, mean ± SD	80.3 ± 7.7	79.2 ± 7.5	**0.0009**	0
Age classes, *n* (%) 65–74 y	142 (25.3)	1207 (29.1)	**0.001**	0
Age classes, *n* (%) 75–84 y	234 (41.7)	1878 (45.2)		0
Age classes, *n* (%) ≥85 y	185 (33.0)	1068 (25.7)		0
Male, *n* (%)	126 (22.5)	2185 (52.6)	**<0.001**	0
Married, *n* (%)	235 (43.1)	2226 (55.4)	**<0.0001**	147
Living alone, *n* (%)	157 (29.2)	865 (22.2)	**0.0003**	283
Having a caregiver, *n* (%)	332 (59.5)	2110 (51.6)	**0.0004**	66
Education level, mean ± SD	7.0 ± 4.1	7.2 ± 4.0	0.26	459
Education level ≥5, *n* (%)	427 (85.4)	3219 (85.7)	0.85	459
BMI, mean ± SD	25.3 ± 5.0	26.0 ± 5.1	**0.0018**	525
BMI classes, *n* (%)				525
BMI <18	21 (4.3)	106 (2.9)	**0.0023**	
18 ≤ BMI < 25	242 (50.0)	1592 (43.0)		
25 ≤ BMI < 30	142 (29.3)	1351 (36.5)		
BMI ≥30	79 (16.3)	656 (17.7)		
CIRS SI, mean ± SD	1.77 ± 0.36	1.65 ± 0.34	**<0.0001**	63
CIRS SI (excluded CIRS 11[a]), mean ± SD	1.70 ± 0.37	1.67 ± 0.35	**0.0220**	63
CIRS CI, mean ± SD	3.60 ± 2.07	2.97 ± 1.87	**<0.0001**	63
CIRS CI (excluded CIRS 11[a]), mean ± SD	3.00 ± 1.94	2.80 ± 1.80	**0.220**	63
Drug number, mean ± SD	6.6 ± 3.2	5.6 ± 2.9	**<0.0001**	149
Polypharmacy, *n* (%)	412 (74.2)	2451 (61.1)	**<0.0001**	149
Drug number (excluded drugs for osteoporosis[b]), mean ± SD	6.1 ± 3.1	5.6 ± 2.9	**0.0011**	149
Polypharmacy (excluded drugs for osteoporosis[b]), *n* (%)	386 (69.6)	2444 (61.0)	**<0.0001**	149
Previous hospitalization, *n* (%)	217 (46.6)	1350 (40.9)	**0.0204**	948
Institutionalized, *n* (%)	30 (5.4)	236 (5.7)	0.74	29

B				
Hemoglobin, mean ± SD	11.5 ± 2.2	11.9 ± 2.3	**0.0016**	40
Creatinine, mean ± SD	1.1 ± 0.8	1.3 ± 0.9	**<0.0001**	60
GDS classes, *n* (%)				60
eGFR class I K-DOQI	66 (11.9)	386 (9.3)	0.23	
eGFR class II K-DOQI	233 (42.1)	1655 (40.4)		
eGFR class III K-DOQI	189 (34.1)	1490 (36.3)		
eGFR class IV K-DOQI	50 (9.0)	425 (10.4)		
eGFR class V K-DOQI	16 (2.9)	144 (3.5)		
GDS classes, *n* (%)				785
Probably not depressed	104 (21.9)	1035 (30.0)	**0.0004**	
Minor depressed	139 (29.2)	995 (28.8)		
Probably depressed	233 (49.0)	1423 (41.2)		
Barthel classes, *n* (%)				1476

Table 1 (continued)

B

No or minimally dependent	165 (40.2)	1491 (52.7)	**<0.0001**	
Mildly dependent	94 (22.9)	522 (18.5)		
Moderately dependent	65 (15.8)	363 (12.8)		
Severely dependent	48 (11.7)	177 (6.3)		
Completely dependent	39 (9.5)	274 (9.7)		
SBT classes, n (%)				482
Normal cognition	166 (33.8)	1476 (39.5)	**0.0362**	
Possible cognitive deficit	85 (17.3)	645 (17.2)		
Probable cognitive deficit	240 (48.9)	1620 (43.3)		

BMI body mass index, CIRS Cumulative Illness Rating Scale, CI Comorbidity Index, SI Severity Index, eGFR estimated glomerular filtration rate, K-DOQI kidney disease outcomes quality initiative, GDS geriatric depression scale, SBT short-blessed test

p values calculated using chi-square or Fisher and Mann–Whitney tests

[a]CIRS 11 = osteoarticular diseases

[b]Bisphosphonates, denosumab, teriparatide, vitamin D, and calcium supplements

Bold values indicate statistical significance $P < 0.05$

Table 2 Drugs taken by osteoporotic patients

Drugs for osteoporosis	Drugs at admission, n (%) N = 482	Drugs at discharge, n (%) N = 482
Vitamin D (ATC A11CC)	101 (21.0)	116 (24.1)
Calcium (ATC A12AA)	29 (6.0)	42 (8.7)
Calcium and vitamin D (ATC A12AX)	70 (14.5)	58 (12.0)
Vitamin D with or without calcium	165 (34.2)	166 (34.4)
Bisphosphonates (ATC M05BA o ATC M05BB)	97 (20.1)	90 (18.7)
Bisphosphonates and vitamin D with or without calcium	37 (7.7)	47 (9.8)
Denosumab (ATC M05BX04)	2 (0.4)	2 (0.4)
Teriparatide (ATC H05AA02)	2 (0.4)	2 (0.4)
SERM (ATC G03XC)	0	0

ATC Anatomical Therapeutic Chemical Classification of the drugs, after excluding those who died in hospital or transferred to another ward. Patients without the following information "drugs at admission" and "drug at discharge" were also excluded

p values calculated using chi-square or Fisher and Mann–Whitney tests

here in Italy, the problem resides outside the hospital, where the diagnosis of osteoporosis was first made, thus confirming what is already known in the literature [2, 3].

Moreover, the proportion of osteoporotic patients treated does not change following discharge resulting in a continuing persistence of undertreatment. This is of ominous prognostic significance since profound consequences regarding morbidity, mortality and especially social costs can be expected by such a behavior. Therefore, it seems that the issue of metabolic bone disease, in general and specifically of osteoporosis, does not capture the attention of doctors at hospital admission and during hospitalization. As a result, hospital physicians are not inclined to prescribe drugs against osteoporosis during hospital stay. This could be due to a number of reasons such as the low awareness of the disease even among skilled doctors [27], or its lower hierarchy in respect to concomitant diseases which have more of an influence on the patient short-term outcomes, as has been previously demonstrated [28].

In our cohort, osteoporotic patients were older, had a mean lower BMI, a higher burden of diseases, and were treated with more drugs compared to non-osteoporotic patients. Moreover, they were more depressed, less independent and with cognitive impairment, all features which rendered them frailer.

As regarding the outcomes, we found that osteoporotic patients showed a higher prevalence of discharge in rehabilitation settings. This may be explained considering their condition of frailty, as mentioned above. Therefore, in the frame of a comprehensive geriatric assessment, it is important to carefully look for a condition of osteoporosis in older hospitalized patients in order to identify those more vulnerable, requiring person-centered approaches (e.g., early inhospital mobilization or selection of the appropriate care setting).

Interestingly, osteoporotic patients seem to be also more vulnerable to the hospitalization-associated disability, showing a higher functional decline, defined in terms of reduction of BI between admission and 3 months after discharge.

We also found that among osteoporotic patients who died during hospital stay, males represented 50% of

Table 3 Outcomes of patients with osteoporosis compared with those without

	Osteoporosis	No osteoporosis	OR/change	p	OR[a]	p[a]	Missing
Inhospital mortality[1]	16 (3.1)	180 (4.8)	0.65 [0.38–1.09]	0.10	0.58 [0.34–1.01]	0.0537	0
Length of stay[1]	11.8 ± 8.4	11.6 ± 9.7		0.52		0.89	12
Nonhome discharged[2]	**54 (14.8)**	**201 (7.9)**	**0.49 [0.36–0.68]**	**<0.0001**	**1.80 [1.28–2.54]**	**0.0007**	1193
Nursing home[2]	19 (5.2)	112 (4.4)		**<0.0001**			
Physical therapy/rehabilitation[2]	**32 (8.8)**	**64 (2.5)**					
Palliative care[2]	3 (0.8)	25 (1.0)					
Three months mortality[3]	35 (9.6)	250 (10.1)	0.94 [0.65–1.37]	0.75	0.97 [0.66–1.43]	0.88	8
Three months rehospitalized[3]	65 (85.5)	381 (88.6)	0.76 [0.38–1.54]	0.44	0.87 [0.41–1.85]	0.72	2336
Three months institutionalized[4]	7 (2.2)	40 (1.9)	1.18 [0.53–2.66]	0.69	0.86 [0.37–1.98]	0.71	278
Functional decline[3] (Barthel 3 months-Barthel admission)	−6.5 ± 19.6	−4.0 ± 17.6	–	0.07	–	0.24	1181

p values calculated using chi-square or Fisher and Mann–Whitney tests

[1]Considering only patients not transferred to other wards (N = 4291), osteoporotic patients: N = 511

[2]Considering only patients not transferred to other wards and who did not die while hospitalized (N = 4095), osteoporotic patients: N = 495

[3]Considering patients who were not transferred to another ward, who did not die while hospitalized, and with data at follow-up (N = 2842), osteoporotic patients: N = 365

[4]Considering patients who were not transferred to another ward, who did not die while hospitalized, and with data at follow-up and who were not admitted from institution (N = 2691), osteoporotic patients: N = 348

[a]Adjusted for age, sex, and CIRS CI

Bold values indicate statistical significance $P < 0.05$

Table 4 Main features of osteoporotic patients taking bisphosphonates vs. those who did not

	Bisphosphonates (n = 108)	No bisphosphonates (n = 447)	p
CIRS SI, mean ± SD	1.7 ± 0.3	1.8 ± 0.4	**0.0006**
CIRS CI, mean ± SD	3.2 ± 1.7	3.7 ± 2.1	**0.0060**
Drug number, mean ± SD	7.3 ± 3.5	6.5 ± 3.1	**0.0408**
Previous hospitalizations, n (%)	31 (36.5)	186 (49.5)	**0.0301**
eGFR, mean ± SD	67.7 ± 23.8	60.2 ± 24.5	**0.0044**
Barthel classes, n (%)			
No or minimally dependent	32 (43.8)	129 (38.7)	**0.0008**
Mildly dependent	28 (38.4)	64 (19.5)	
Moderately dependent	6 (8.2)	59 (17.7)	
Severely dependent	4 (5.5)	44 (13.2)	
Completely dependent	3 (4.1)	36 (10.8)	

Only results that were statistically significant are reported in this table

eGFR estimated glomerular filtration rate, CIRS Cumulative Illness Rating Scale, CI Comorbidity Index, SI Severity Index

p values calculated using chi-square or Fisher and Mann–Whitney tests

Bold values indicate statistical significance $P < 0.05$

patients, a percentage significantly higher than the percentage of men among survivors (21.7%, $p = 0.007$). Moreover, those who died had a significantly higher rate of a previous hospitalization or were admitted from nursing facilities and were less dependent, further emphasizing the concept of frailty.

Interestingly, several variables may affect physicians' choice in osteoporosis treatment. Bisphosphonates were more prescribed to subjects with a lower comorbidity burden and more independent.

We found, that among patients who died after 3 months' follow-up, vitamin D supplements were significantly less prescribed, as well as bisphosphonates, although for bisphosphonates this difference was not statistically significant. A recent paper points to the role of serum vitamin D levels and mortality in subjects at least 80 years old [29].

This prospective multicenter, community-based cohort study of 2185 Chinese older adults, with a median age of 93 years, showed that in this population, after adjusting for multiple confounders, the risk of all-cause mortality decreased as the plasma 25(OH)D concentration increased [29]. Even though there is an ongoing debate about the role of vitamin D (and bisphosphonates) and survival, we believe that our findings should be interpreted with caution also considering the small number of patients enrolled. In this context, for example, it has been reported that compliance to treatment can be simply considered a surrogate of well-being in respect to those non adherent [27, 30]

Our study has limitations and strengths. The REPOSI Study was not designed to collect osteoporosis-related variables. Therefore, no information on morphometric vertebral fractures are available in the REPOSI dataset; as a consequence, the number of osteoporotic patients may be further underestimated. Furthermore, we do not have information regarding densitometric parameters, as well as on some relevant biochemical measurements, i.e., serum vitamin D levels. As a result, analysis on the appropriateness of osteoporosis-related drugs, according to the validated scores, are not possible. Missing data for some patients is one of the limits, even though this does not change the final conclusions of our study.

Despite these limits, we have characterized, for the first time, a cohort of patients admitted to internal medicine and geriatric wards with a concomitant diagnosis of osteoporosis.

In conclusion, we report that in internal medicine wards, the diagnosis of osteoporosis is neglected both during hospital stay and at discharge, therefore substantially contributing to the economic and social burden of the disease. A cultural change is urgently required for the way hospital specialists view and treat metabolic bone diseases and, in particular, osteoporosis.

Reposi investigators Pier Mannuccio Mannucci[4], Antonello Pietrangelo[5], Francesco Perticone[6], Francesco Violi[7], Gino Roberto Corazza[8], Salvatore Corrao[920], Alessandra Marengoni[10,32], Francesco Salerno[11,46], Matteo Cesari[12], Luca Pasina[13], Carlotta Franchi[13], Laura Cortesi[13], Gabriella Miglio[13], Ilaria Ardoino[13], Alessio Novella[13], Domenico Prisco[14], Elena Silvestri[14], Giacomo Emmi[14], Alessandra Bettiol[14], Irene Mattioli[14], Gianni Biolo[15], Michela Zanetti[15], Giacomo Bartelloni[15], Massimo Vanoli[16], Giulia Grignani[16], Edoardo Alessandro Pulixi[16], Graziana Lupattelli[17], Vanessa Bianconi[17], Riccardo Alcidi[17], Domenico Girelli[18], Fabiana Busti[18], Giacomo Marchi[18], Mario Barbagallo[19], Ligia Dominguez[19], Vincenza Beneduce[19], Federica Cacioppo[19], Giuseppe Natoli[20], Salvatore Mularo[20], Massimo Raspanti[20], Marco Zoli[21], Maria Laura Matacena[21], Giuseppe Orio[21], Eleonora Magnolfi[21], Giovanni Serafini[21], Angelo Simili[21], Giuseppe Palasciano[22], Maria Ester Modeo[22], Carla Di Gennaro[22], Maria Domenica Cappellini[23], Giovanna Fabio[23], Margherita Migone De Amicis[23], Giacomo De Luca[23], Natalia Scaramellini[23], Matteo Cesari[24], Paolo Dionigi Rossi[24], Sarah Damanti[24], Marta Clerici[24], Simona Leoni[24], Alessandra Danuta Di Mauro[24], Antonio Di Sabatino[8], Emanuela Miceli[8], Marco Vincenzo Lenti[8], Martina Pisati[8], Costanza Caccia Dominioni[8], Roberto Pontremoli[25], Valentina Beccati[25], Giulia Nobili[25], Giovanna Leoncini[25], Luigi Anastasio[26], Maria Carbone[26], Francesco Cipollone[27], Maria Teresa Guagnano[27], Ilaria Rossi[27], Gerardo Mancuso[28], Daniela Calipari[28], Mosè Bartone[28], Giuseppe Delitala[29], Maria Berria[29], Alessandro Delitala[29], Maurizio Muscaritoli[30], Alessio Molfino[30], Enrico Petrillo[30], Antonella Giorgi[30], Christian Gracin[30], Giuseppe Zuccalà[31], Gabriella D'Aurizio[31], Giuseppe Romanelli[32], Andrea Volpini[32], Daniela Lucente[32], Antonio Picardi[33], Umberto Vespasiani Gentilucci[33], Paolo Gallo[33], Giuseppe Bellelli[34], Maurizio Corsi[34], Cesare Antonucci[34], Chiara Sidoli[34], Giulia Principato[34], Franco Arturi[35], Elena Succurro[35], Bruno Tassone[35], Federica Giofrè[35], Maria Grazia Serra[36], Maria Antonietta Bleve[36], Antonio Brucato[37], Teresa De Falco[37], Fabrizio Fabris[38], Irene Bertozzi[38], Giulia Bogoni[38], Maria Victoria Rabuini[38], Tancredi Prandini[38], Roberto Manfredini[39], Fabio Fabbian[39], Benedetta Boari[39], Alfredo De Giorgi[39], Ruana Tiseo[39], Giuseppe Paolisso[40], Maria Rosaria Rizzo[40], Claudia Catalano[40], Claudio Borghi[21], Enrico Strocchi[21], Eugenia Ianniello[21], Mario Soldati[21], Silvia Schiavone[21], Alessio Bragagni[21], Carlo Sabbà[41], Francesco Saverio Vella[41], Patrizia Suppressa[41], Giovanni Michele De Vincenzo[41], Alessio Comitangelo[41], Emanuele Amoruso[41], Carlo Custodero[41], Luigi Fenoglio[42], Andrea Falcetta[42], Anna L. Fracanzani[43], Silvia Tiraboschi[43], Annalisa Cespiati[43], Giovanna Oberti[43], Giordano Sigon[43], Flora Peyvandi[44], Raffaella Rossio[44], Giulia Colombo[44], Valter Monzani[45], Valeria Savojardo[45], Giuliana Ceriani[45], Giada Pallini[46], Fabrizio Montecucco[47], Luciano Ottonello[47], Lara Caserza[47], Giulia Vischi[47], Nicola Lucio Liberato[48], Tiziana Tognin[48], Francesco Purrello[49], Antonino Di Pino[49], Salvatore Piro[49], Renzo Rozzini[50], Lina Falanga[50], Maria Stella Pisciotta[50], Francesco Baffa Bellucci[50], Stefano Buffelli[50], Giuseppe Montrucchio[51], Paolo Peasso[51], Edoardo Favale[51], Cesare Poletto[51], Carl Margaria[51], Maura Sanino[51], Ludovica Perri[7], Luigina Guasti[52], Luana Castiglioni[52], Andrea Maresca[52], Alessandro Squizzato[52], Leonardo Campiotti[52], Alessandra Grossi[52], Roberto Davide Diprizio[52], Marco Bertolotti[53,54], Chiara Mussi[53,54], Giulia Lancellotti[53,54], Maria Vittoria Libbra[53,54], Matteo Galassi[53,54], Yasmine Grassi[53,54], Alessio Greco[53,54], Angela Sciacqua[55], Maria Perticone[55], Rosa Battaglia[55], Raffaele Maio[55], Vincenzo Stanghellini[56], Eugenio Ruggeri[56], Sara del Vecchio[56], Andrea Salvi[57], Roberto Leonardi[57], Giampaolo Damiani[57], William Capeci[58], Massimo Mattioli[58], Giuseppe Pio Martino[58], Lorenzo Biondi[58], Pietro Pettinari[58], Riccardo Ghio[59], Anna Dal Col[59], Giancarlo Labbadia[60], Antonella Afeltra[61], Benedetta Marigliano[61], Maria Elena Pipita[61], Pietro Castellino[62], Luca Zanoli[62], Alfio Gennaro[62], Agostino Gaudio[62], Valter Saracco[63], Marisa Fogliati[63], Carlo Bussolino[63], Francesca Mete[64], Miriam Gino[64], Carlo Vigorito[65], Antonio Cittadini[65], Guido Moreo[66], Silvia Prolo[66], Gloria Pina[66], Alberto Ballestrero[67], Fabio Ferrando[67], Roberta Gonella[67], Domenico Cerminara[67], Sergio Berra[68], Simonetta Dassi[68], Maria Cristina Nava[68], Bruno Graziella[69], Stefano Baldassarre[69], Salvatore Fragapani[69], Gabriella Gruden[69], Giorgio Galanti[70], Gabriele Mascherini[70], Cristian Petri[70], Laura Stefani[70], Margherita Girino[71], Valeria Piccinelli[71], Francesco Nasso[72], Vincenza Gioffrè[72], Maria Pasquale[72], Leonardo Sechi[73], Cristiana Catena[73], Gianluca Colussi[73], Alessandro Cavarape[73], Andea Da Porto[73], Nicola Passariello[74], Luca Rinaldi[74], Franco Berti[75], Giuseppe Famularo[75], Patrizia Tarsitani[75], Roberto Castello[76], Michela Pasino[76], Gian Paolo Ceda[77], Marcello Giuseppe Maggio[77], Simonetta Morganti[77], Andrea Artoni[77], Margherita Grossi[77], Stefano Del Giacco[78], Davide Firinu[78], Giulia Costanzo[78], Giacomo Argiolas[78], Giuseppe Montalto[79], Anna Licata[79], Filippo Alessandro Montalto[79], Francesco Corica[80], Giorgio Basile[80], Antonino Catalano[80], Federica Bellone[80], Concetto Principato[80], Lorenzo Malatino[81], Benedetta Stancanelli[81], Valentina Terranova[81], Salvatore Di Marca[81], Rosario Di Quattro[81], Lara La Malfa[81], Rossella Caruso[81], Patrizia Mecocci[82], Carmelinda Ruggiero[82], Virginia Boccardi[82], Tiziana Meschi[83], Andrea Ticinesi[83], Antonio Nouvenne[83], Pietro Minuz[84], Luigi Fondrieschi[84], Giandomenico Nigro Imperiale[84], Mario Pirisi[85], Gian Paolo Fra[85], Daniele Sola[85], Mattia Bellan[85],

Massimo Porta[86], Piero Riva[86], Roberto Quadri[87], Erica Larovere[87], Marco Novelli[87], Giorgio Scanzi[88], Caterina Mengoli[88], Stella Provini[88], Laura Ricevuti[88], Emilio Simeone[89], Rosa Scurti[89], Fabio Tolloso[89], Roberto Tarquini[90], Alice Valoriani[90], Silvia Dolenti[90], Giulia Vannini[90], Riccardo Volpi[90], Pietro Bocchi[91], Alessandro Vignali[91], Sergio Harari[92], Chiara Lonati[92], Federico Napoli[92], Italia Aiello[92], Raffaele Landolfi[93], Massimo Montalto[93], Antonio Mirijello[93], Francesco Purrello[94], Antonino Di Pino[94], Silvia Ghidoni[95], Teresa Salvatore[96], Lucio Monaco[96], Carmen Ricozzi[96], Alberto Pilotto[97], Ilaria Indiano[97], Federica Gandolfo[97]

[4]Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy; [5]Center for Hemochromatosis, Department of Internal Medicine II, University of Modena and Reggio Emilia Policlinico, Modena, Italy; [6]Department of Medical and Surgical Sciences, University Magna Græcia of Catanzaro, 88100 Catanzaro, Italy; [7]Policlinico Umberto I, Prima Clinica Medica, Roma, Italy; [8]Clinica Medica I, Reparto 11, IRCCS Policlinico San Matteo di Pavia, Pavia, Italy; [9]ARNAS Civico, Di Cristina, Benfratelli, DiBiMIS, Università di Palermo, Palermo, Italy; [10]Spedali Civili di Brescia, Brescia, Italy; [11]IRCCS Policlinico San Donato Milanese, Milano, Italy; [12]UO Geriatria, Università degli Studi di Milano, Milano, Italy; [13]Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy; [14]Medicina Interna Interdisciplinare, Azienda Ospedaliero Universitaria Careggi Firenze, Firenze, Italy; [15]Clinica Medica Generale e Terapia Medica, Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, Italy; [16]Ospedale di Merate, Medicina Interna, Azienda Ospedaliera della Provincia di Lecco, Lecco, Italy; [17]Medicina Interna, Azienda Ospedaliera Santa Maria della Misericordia, Perugia, Italy; [18]Medicina Generale e Malattie Aterotrombotiche e Degenerative, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy; [19]Unità Operativa di Geriatria e Lungodegenza, Azienda Ospedaliera Universitaria Policlinico Giaccone Policlinico di Palermo, Palermo, Italy; [20]A.R.N.A.S. Civico, Di Cristina, Benfratelli, UOC Medicina Interna ad Indirizzo Geriatrico-Riabilitativo, Palermo, Italy; [21]Unità Operativa di Medicina Interna Borghi, Azienda Ospedaliera Universitaria Policlinico S. Orsola-Malpighi, Bologna, Italy; [22]Medicina Interna Ospedaliera "L. D'Agostino", Medicina Interna Universitaria "A. Murri", Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Bari, Italy; [23]Unità Operativa Medicina Interna IA, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy; [24]Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Geriatria, Milano, Italy; 25Clinica di Medicina Interna 2, IRCCS Azienda Ospedaliera Universitaria San Martino-IST di Genova, Genova, Italy; [26]Medicina interna, Ospedale Civile Jazzolino di Vibo Valentia, Vibo Valentia, Italy; [27]Clinica Medica, Ospedale Clinicizzato SS. Annunziata, Chieti, Italy; [28]Ospedale Giovanni Paolo II Lamezia Terme, Unità Operativa Complessa Medicina Interna, Catanzaro, Italy; [29]Clinica Medica, Azienda ospedaliera-universitaria di Sassari, Sassari, Italy; 30Medicina Interna e Nutrizione Clinica, Sapienza University, Roma, Italy; [31]Policlinico Universitario A. Gemelli, Roma, Italy; 32Unità Operativa Complessa di Medicina I a indirizzo geriatrico, Spedali Civili, Montichiari, Brescia, Italy; [33]Medicina Clinica-Epatologia, Università Campus Bio-Medico, Roma, Italy; [34]Ospedale S. Gerardo, Unità Operativa di Geriatria, Università degli studi di Milano-Bicocca, Monza, Italy; [35]Unità Operativa Complessa di Medicina Interna, Policlinico Mater Domini, Università degli Studi Magna Grecia, Catanzaro, Italy; [36]Azienda Ospedaliera "Cardinale Panico" Tricase, Unità Operativa Complessa Medicina, Lecce, Italy; [37]ASST Fatebenefratelli-Sacco, Medicina Interna, Milano, Italy; [38]Clinica Medica I, Azienda Ospedaliera Università di Padova, Padova, Italy; 39Unità Operativa Clinica Medica, Azienda Ospedaliera-Universitaria Sant'Anna, Ferrara, Italy; [40]VI Divisione di Medicina Interna e Malattie Nutrizionali dell'Invecchiamento, Azienda Ospedaliera Universitaria della Seconda Università degli Studi di Napoli, Napoli, Italy; [41]Medicina Interna Universitaria C. Frugoni, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Bari, Italy; 42Azienda Sanitaria Ospedaliera Santa Croce e Carle di Cuneo, S. C. Medicina Interna, Cuneo, Italy; [43]Medicina Interna 1B, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy; 44UOC Medicina generale—Emostasi e trombosi, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy; [45]Medicina Interna Alta Intensità, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy; [46]San Donato Milanese, Medicina Interna, IRCCS Policlinico San Donato e Università di Milano, Milano, Italy; [47]Medicina Interna 1, IRCCS Ospedale Policlinico San Martino e Università di Genova, Genova, Italy; [48]ASST di Pavia, UOSD Medicina Interna, Ospedale di Casorate Primo, Pavia, Italy; 49Unità Operativa Complessa di Medicina Interna, Ospedale Garibaldi Nesima, Catania, Italy; [50]Ospedale Poliambulanza, Medicina Interna e Geriatria, Brescia, Italy; [51]Dipartimento di Scienze Mediche, Città della Scienza e della Salute, Medicina Interna 2 U. Indirizzo d'Urgenza, Università di Torino, Torino, Italy; [52]Ospedale di Circolo e Fondazione Macchi, Medicina Interna I, Università degli Studi dell'Insubria, Varese, Italy; [53]Azienda Ospedaliero-Universitaria di Modena, Università di Modena e Reggio Emilia, Modena, Italy; 54Unità Operativa di Geriatria, Ospedale Civile di Baggiovara, Modena, Italy; 55Unità Operativa Malattie Cardiovascolari Geriatriche, Università Magna Grecia Policlinico Mater Domini, Catanzaro, Italy; 56Dipartimento di Scienze Mediche e ChirurgicheUnità Operativa di Medicina Interna, Università degli Studi di Bologna/Azienda Ospedaliero-Universitaria S.Orsola-Malpighi, Bologna, Italy; [57]Spedali Civili di Brescia, U.O. 3a Medicina Generale, Brescia, Italy; 58Clinica Medica, Azienda Ospedaliera Universitaria—Ospedali Riuniti di Ancona, Ancona, Italy; [59]Azienda Ospedaliera Università San Martino, Medicina III, Genova, Italy; [60]Policlinico Umberto I, SMSC03—Medicina Interna A e Malattie Metaboliche dell'osso, Roma, Italy; [61]Policlinico Campus Biomedico Roma, Medicina Clinica, Roma, Italy; [62]V. Emanuele, Dipartimento di Medicina, Azienda Ospedaliera Universitaria Policlinico–V, Catania, Italy; [63]Medicina A, Ospedale Cardinal Massaia Asti, Asti, Italy; [64]Ospedale degli Infermi di Rivoli, Torino, Medicina Interna, Turin, Italy; [65]Medicina Interna e Riabilitazione Cardiologica, Azienda Policlinico Universitario Federico II di Napoli, Napoli, Italy; [66]Clinica San Carlo Casa di Cura Polispecialistica, Paderno Dugnano, Unità Operativa di Medicina Interna, Milano, Italy; [67]Clinica Di Medicina Interna ad Indirizzo Oncologico, Azienda Ospedaliera Università San Martino di Genova, Genoa, Italy; [68]Medicina Interna, Azienda Ospedaliera Guido Salvini, Garnagnate, Milano, Italy; [69]Medicina Interna III, Ospedale S. Giovanni Battista Molinette, Torino, Turin, Italy; [70]Agenzia di Medicina dello Sport, AOUC Careggi, Firenze, Italy; [71]Medicina Interna, Ospedale S. Spirito Casale Monferrato, Alessandria, Italy; [72]Struttura Operativa Complessa di Medicina Interna, Ospedale Santa Maria degli Ungheresi, Reggio Calabria, Italy; [73]Clinica Medica, Azienda Ospedaliera Universitaria, Udine, Italy; [74]Presidio Medico di Marcianise, Medicina Interna, Napoli, Italy; [75]Azienda Ospedaliera San Camillo Forlanini, Medicina Interna II, Roma, Italy; [76]Medicina Generale e Sezione di Decisione Clinica, Ospedale Civile Maggiore Borgo Trento, Verona, Italy; [77]U.O.C Clinica Geriatrica, Azienda Ospedaliero Universitaria di Parma, Parma, Italy; [78]Policlinico Universitario Duilio Casula,Medicina Interna, Allergologia ed Immunologia Clinica, Azienda Ospedaliero-Universitaria di Cagliari, Cagliari, Italy; [79]UOC di Medicina Interna, Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, Italy; [80]Unità Operativa di Geriatria, Azienda Ospedaliera Universitaria Policlinico G. Martino, Messina, Italy; [81]Azienda Ospedaliera per l'Emergenza Cannizzaro, Clinica Medica Università di Catania, Catania, Italy; [82]Università degli Studi di Perugia-Azienda Ospedaliera S.M. della Misericordia, Struttura Complessa di Geriatria, Perugia, Italy; [83]U.O Medicina Interna e Lungodegenza Critica, Azienda Ospedaliera Universitaria di Parma,

Parma, Italy; [84]Policlinico GB Rossi, Medicina Generale per lo Studio ed il Trattamento dell'Ipertensione Arteriosa, Azienda Ospedaliera Universitaria Verona, Verona, Italy; [85]Medicina Interna 1, Azienda Ospedaliera Universitaria Maggiore della Carità, Novara, Italy; 86Medicina Interna 1U, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy; [87]Ospedale di Ciriè, ASL TO4, Torino, S.C. Medicina Interna, Turin, Italy; [88]ASST Lodi, Presidio di Codogno, Medicina, Milano, Italy; [89]Ospedale Spirito Santo di Pescara, Geriatria, Pescara, Italy; [90]Ospedale San Giuseppe, Empoli, USL Toscana Centro, Medicina Interna I, Firenze, Italy; [91]Clinica e Terapia Medica, Azienda Ospedaliera Universitaria di Parma, Parma, Italy; [92]U.O. Medicina Generale, Ospedale San Giuseppe Multimedica Spa, Milan, Italy; [93]Policlinico Universitario A. Gemelli —Roma, Clinica Medica, Roma, Italy; [94]U.O.C Medicina Interna, Ospedale Garibaldi—Nesima—Catania, Catania, Italy; [95]Azienda Ospedaliera Papa Giovanni XXIII, Medicina I, Bergamo, Italy; [96]UOC Medicina Internaa, Policlinico Università della Campania L. Vanvitelli, Roma, Italy; [97]SC Geriatria Dipartimento Cure Geriatriche, Ortogeriatria e Riabilitazione, Ente Ospedaliero Ospedali Galliera Genova, Genova, Italy

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

References

1. E. Hernlund, A. Svedbom, M. Ivergård, J. Compston, C. Cooper, J. Stenmark, E.V. McCloskey, B. Jönsson, J.A. Kanis, Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the international osteoporosis foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch. Osteoporos. **8**, 136 (2013)

2. P.D. Miller, Underdiagnosis and undertreatment of osteoporosis: the battle to be won. J. Clin. Endocrinol. Metab. **101**, 852–859 (2016)

3. J. Flais, G. Coiffier, J. Le Noach, J.D. Albert, M. Faccin, A. Perdriger, H. Thomazeau, P. Guggenbuhl, Low prevalence of osteoporosis treatment in patients with recurrent major osteoporotic fracture. Arch. Osteoporos. **12**, 24 (2017)

4. S. Gonnelli, C. Caffarelli, G. Iolascon, F. Bertoldo, G.L. Mauro, A. Patti, R. Nuti, Prescription of anti-osteoporosis medications after hospitalization for hip fracture: a multicentre Italian survey. Aging Clin. Exp. Res. **29**, 1031–1037 (2017)

5. K. Johnell, J. Fastbom, Undertreatment of osteoporosis in the oldest old? A nationwide study of over 700,000 older people. Arch. Osteoporos. **4**, 17–23 (2009)

6. O. Strom, F. Borgstrom, S.S. Sen, S. Boonen, P. Haentjens, O. Johnell, J.A. Kanis, Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries—an economic evaluation based on the fracture intervention trial. Osteoporos. Int. **18**, 1047–1061 (2007)

7. M.T. Puth, M. Klaschik, M. Schmid, K. Weckbecker, E. Münster, Prevalence and comorbidity of osteoporosis- a cross-sectional analysis on 10,660 adults aged 50 years and older in Germany. BMC Musculoskelet. Disord. **19**, 144 (2018)

8. J.P. Gutzwiller, J.P. Richterich, Z. Stanga, U.E. Nydegger, L. Risch, M. Risch, Osteoporosis, diabetes, and hypertension are major risk factors for mortality in older adults: an intermediate report on a prospective survey of 1467 community-dwelling elderly healthy pensioners in Switzerland. BMC Geriatr. **18**, 115 (2018)

9. I.D. Cameron, J.S. Chen, L.M. March, J.M. Simpson, R.G. Cumming, M.J. Seibel, P.N. Sambrook, Hip fracture causes excess mortality owing to cardiovascular and infectious disease in institutionalized older people: a prospective 5-year study. J. Bone Miner. Res. **25**, 866–872 (2010)

10. L. Bondo, P. Eiken, B. Abrahamsen, Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients-a nationwide register-based open cohort study. Osteoporos. Int. **24**, 245–252 (2013)

11. L.A. Beaupre, D.W. Morrish, D.A. Hanley, W.P. Maksymowych, N.R. Bell, A.G. Juby, S.R. Majumdar, Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos. Int. **22**, 983–991 (2011)

12. J.R. Center, D. Bliuc, N.D. Nguyen, T.V. Nguyen, J.A. Eisman, Osteoporosis medication and reduced mortality risk in elderly women and men. J. Clin. Endocrinol. Metab. **96**, 1006–1014 (2014)

13. P.N. Sambrook, I.D. Cameron, J.S. Chen, L.M. March, J.M. Simpson, R.G. Cumming, M.J. Seibel, Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos. Int. **22**, 2551–2556 (2011)

14. P. Lee, C. Ng, A. Slattery, P. Nair, J.A. Eisman, J.R. Center, Preadmission bisphosphonate and mortality in critically ill patients. J. Clin. Endocrinol. Metab. **101**, 1945–1953 (2016)

15. S.R. Cummings, L.Y. Lui, R. Eastell, I.E. Allen, Association between drug treatments for patients with osteoporosis and overall mortality rates: a meta-analysis. JAMA Intern. Med. **179**, 1491–1500 (2019)

16. M.D. Neuman, J.H. Silber, J.S. Magaziner, M.A. Passarella, S. Mehta, R.M. Werner, Survival and functional outcomes after hip fracture among nursing home residents. JAMA Intern. Med. **174**, 1273–1280 (2014)

17. L.A. Beaupre, S.R. Majumdar, S. Dieleman, A. Au, D.W. Morrish, Diagnosis and treatment of osteoporosis before and after admission to long-term care institutions. Osteoporos. Int. **23**, 573–580 (2011)

18. S. Parikh, H. Mogun, J. Avorn, D.H. Solomon, Osteoporosis medication use in nursing home patients with fractures in 1 US state. Arch. Intern. Med. **168**, 1111–1115 (2008)

19. A. Nobili, G. Licata, F. Salerno, L. Pasina, M. Tettamanti, C. Franchi, L. De Vittorio, A. Marengoni, S. Corrao, A. Iorio, M. Marcucci, P.M. Mannucci; SIMI Investigators, Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur. J. Clin. Pharmacol. **67**, 507–519 (2011)

20. F. Salvi, V. Morichi, A. Grilli, R. Giorgi, L. Spazzafumo, S. Polonara, G. De Tommaso, A. Rappelli, P. Dessì-Fulgheri, A geriatric emergency service for acutely ill elderly patients: pattern of use and comparison with a conventional emergency department in Italy. J. Am. Geriatr. Soc. **56**, 2131–2138 (2008)

21. P.A. Parmelee, P.D. Thuras, I.R. Katz, M.P. Lawton, Validation of the cumulative illness rating scale in a geriatric residential population. J. Am. Geriatr. Soc. **43**, 130–137 (1995)

22. S. Shah, F. Vanclay, B. Cooper, Improving the sensitivity of the Barthel index for stroke rehabilitation. J. Clin. Epidemiol. **42**, 703–709 (1989)

23. R. Katzman, T. Brown, P. Fuld, A. Peck, R. Schechter, H. Schimmel, Validation of a short orientation-memory-

concentration test of cognitive impairment. Am. J. Psychiatry **140**, 734–739 (1983)

24. C. Hickie, J. Snowdon, Depression scales for the elderly: GDS, Gilleard, Zung. Clin. Gerontol. J. Aging Ment. Health **6**, 51–53 (1987)

25. R. Nuti, M.L. Brandi, G. Checchia, O. Di Munno, L. Dominguez, P. Falaschi, C.E. Fiore, G. Iolascon, S. Maggi, R. Michieli, S. Migliaccio, S. Minisola, M. Rossini, G. Sessa, U. Tarantino, A. Toselli, G.C. Isaia, Guidelines for the management of osteoporosis and fragility fractures. Intern. Emerg. Med. **14**, 85–102 (2019)

26. C. Cipriani, J. Pepe, F. Bertoldo, G. Bianchi, F.P. Cantatore, A. Corrado, M. Di Stefano, B. Frediani, D. Gatti, A. Giustina, T. Porcelli, G. Isaia, M. Rossini, L. Nieddu, S. Minisola, G. Girasole, M. Pedrazzoni, The epidemiology of osteoporosis in Italian postmenopausal women according to the National Bone Health Alliance (NBHA) diagnostic criteria: a multicenter cohort study. J. Endocrinol. Investig. **41**, 431–438 (2018)

27. P. Donato, J. Pepe, L. Colangelo, V. Danese, V. Cecchetti, S. Minisola, C. Cipriani, Adherence to bisphosphonates in the general population: a retrospective study in patients referred to a primary care service. Arch. Osteoporos. **14**, 42 (2019)

28. J. Pepe, C. Cipriani, V. Cecchetti, C. Ferrara, G. Della Grotta, V. Danese, L. Colangelo, S. Minisola, Patients' reasons for adhering to long-term alendronate therapy. Osteoporos. Int. **30**, 1627–1634 (2019)

29. C. Mao, F.R. Li, Z.X. Yin, Y.B. Lv, J.S. Luo, J.Q. Yuan, F. Mhungu, J.N. Wang, W.Y. Shi, J.H. Zhou, G.C. Chen, X. Gao, V. B. Kraus, X.B. Wu, X.M. Shi, Plasma 25-Hydroxyvitamin D concentrations are inversely associated with all-cause mortality among a prospective cohort of Chinese adults aged ≥80 years. J. Nutr. **149**, 1056–1064 (2019)

30. F. Fatoye, P. Smith, T. Gebrye, G. Yeowell, Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open **9**(4), e027049 (2019)